Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't be discouraged, things are just coming to fruition
New team cleaning up prior teams errors. Strengthen board, reduced costs and focus on higher margin products. They still have many hurdles to over come but they renewed focus and still have three committed large pharma's under contract. Financials still of oncern, but OrbiMed and Amgen ontrolling direction.
Watching Sanofi drug approvals this month. Maybe in a Unilife device.
Hope you are wrong! But I should have sold long ago
Management continues to flounder and security/investors will pay the price while they try to figure out what to do....Short/Long term sell...this company will not recover from prior corrupt management team...
Apparently you live in the land of unicorns and rainbows...did you read the last Q at all...that thing is a total train wreck. They are going to have to pay folks to divest of assets...While I can appreciate leadership trying to consolidate the company to focus efforts...near term....at least next 12 months...this is going to be a train wreck....the PPS is reflecting it day by day as it continues to slowly erode....suspect you will break the 2.00 mark this week and into next and settle around 1.50 ballpark in a few months...There is NOTHING short term to see any appreciation on this security....NOTHING!
A year from now you'll likely be paying over $10 a share.
That 10Q looked like a nightmare...all the rest is wild speculation with no facts to support. Any NDA would take a year plus and they are looking to divest all other deals outside the wearable injectors, of which they are going to have to pay to get out of....simply, they are consolidating and it will cost them short term....They may turn it around, but financing and dilution will likely be in the very near future, along with much more debt...I may consider putting money in once they have at least a proven play....likely a year plus from now, but short term the forecast is pain and lots of it...
There are several drugs in various stages of their drug trials that upon completion and successful FDA approval will be utilizing our wearable injectors. Commercial production could start pretty soon. Its a waiting game. The 10Q cant tell the whole story as to what is about to take place obviously due to the confidentiality of these deals. We are very close. Im just hoping for a financing deal to see it through then boom.
This mornings 10Q is a nightmare....decreasing revenues, debt and convertibles are running rampant and do not see any near term prospects to turn things around....I have never heard of an accelerated convertible note...lol. That is a new one....Needless to say, sold with a small loss and will not be back! Sorry UNIS, but your quarterly looks like a nightmare with no end in sight....
JPM has had a large state for years. SP will move based on business deals and future contracts.
Hanging over the SP is exiting the PFS contracts without financial pain to the company.
In additional, the sale of the York facility or maybe sale lease back. Unknown as of yet.
Angem, Sanofi and AZT are under contracts. Ryan indicated a few years out revenue will kick in.
Company has large IP portfolio. Value???
I'm adding and look to 2018 (July) to start rise in SP. JHMO.
Check out IGXT
railroadman with the raise in pps the passed month and the report of jp morgans holding. is this going to really take off??
Happy New Year RRM!
Reading about a company called Jabil. Seams to be gaining in some of UNIS pfs and Ez mix space.
Company unannounced plans for other products that are tabled except for the IP portfolio needs to be announced soon. I would expect it has good value.
OrbiMed will want to get more cash on the books. JMHO.
Azt announced a drug in a delivery device in a Depot Injection?? Interesting.
Happy New Year. RRM
Really looking forward to Ryan giving updates on Contracts programs and devices. Add IP patents and status of existing contracts and their exit plan for PFS.
Completely agree. Unilife has more potential than any other micro cap stock ive ever followed. We are entering a new drug age of injectable biologics and Unilife is uniquely piggy backing big pharma in a way that allows them to reap the financial benefits of any FDA approved drug utilizing their wearable injector.
Retail - Sing on now and you can have some 1 dollar shares soon enough....
Corruption and ineptness are the name of the game is you work in/with UNIS....Come and get your soon to be worthless paper now!!!
Security collapsing right back to where it was with previous corrupt management. Unfortunately when you have morally bankrupt folks involved in a company, especially the leaders, it breads and becomes part of the organization, often leading to a death knell for the company. This appears to be the case with UNIS and will be until proven differently. Over the past few weeks it has given up much of the gains and now close to where its value was with corrupt management. Unfortunately some things don't change when leaders are removed....the void is filled with the same bile that was already present within the company...
Respect your views. But I'm still adding at these prices with the understanding of the 2/3 time frame.
Understand the past. Former CEO was not good for shareholders. He was not held accountable by the board.
Ryan will secure the future. Positive feeling about board additions. JMHO
YET, your company continues to go slowly in the crapper! 100% on board with removal of corruption/criminals, only problem is they destroyed the company in the process. Like removing cancer from patient, yet killing the host in the process...either way, investors lose. Investing here is a slow death....NO THANKS!!! There is zero value!
2016! Remove chairman, president , restructured the board, closed investigation, progress Amgen contract, phase out PFS line ( appears to indicated contracts were not profitable, plant up for sale,reduct workforce by 50% introduce new handheld injector.
3 contracts with large pharma still progressing well. Other potential pharma's had or have reservations about execution capabilities. Ryan and team addressing.
Pursuing other customers Radigan and Ian. Who unknown??
Clinical testing in Nov. announce company very pleased with results.
Company stating they have the best wearable technology. 3 steps vs other device suppliers with a 9 step process which is complexity in the world of focus on simplicity.
Cost structure down. Ryan playing it close to the vest. No AS over promising.
Value of the PFS contracts and patents unknown. Ryan charged with renegotiating contracts if possible.
Nothing said on Novartis program or Ocuject or AbbVie? Hidden value or hidden expense to resolve.
$26 million write down in 2016. Clear sailing in 2017 and beyond.
Still hiring. Happy holidays to all.
Sounds like they need cash and dilution coming
You own CEO took a giant shat right on the security...expect to see this continually decline until they can execute and proves some improvement....company appears in shambles and PPS is confirming this assessment from the street/market
sounds like you are wrong. I bought during the run up in the 2.53 range up to 2.58 and exited at 2.80 price points...it has executed the run up off of the depressed lows due to the investigation and not being current. Now that that is complete, there are no other catalyst for PPS appreciation....will settle back down and trade in 2.30-2.70 range....
sounds like
you sold for a loss recently, no worries....short it if you can
After reviewing the recent filings, I will be placing a substantial short in on this....they apparently are producing little to nothing except R&D along with substantial costs associated with management and payroll. This combined with two new paychecks for recently added insiders....appears management is more concerned with their own paychecks versus creating value for owners/shareholders.
In short....this appears uglier by the day!
Got this combined with a ton of liquidity above 2.60/2.70 and MMs playing grab ass with the PPS....not liking the action here. They definitely need to get their act together and fast as MMs are just waiting to create a feeding frenzy on the short side. Given the past trading and security is all out of wack given the huge spike recently; could easily correct back down to dollar range if management does not provide a clear way forward with some revenue/profit to sustain the recent move...
less than two and Half days until we get the first financial conference call. Looking for the concrete condition of the company from Ryan and team. Status of programs and customer contracts and the strategy to exit PFS business and how existing contracts will be handled.
Company indicating that certain business segments were not profitable.
UNIS 3.00+ looking good here
One of the most undervalued securities I am watching. Will continue to climb and gap. MACD is about to go positive and technical and accordingly the algorithms that run most of the trading will turn positive as well. Expect 4 dollars shortly and expect to climb back up to 5.50 range before settling in. Hugely undervalued here and adding at every opportunity. Will keep loading until I have over 80K invested here....huge opportunity...
Looking forward to this call. First Quarter could bring some positive items. Retreated yesterday which is normal after good trading move. RD spend was still large in 2016. Charges for write offs done in 2016.
Bad news is behind us. Company still has large deferred revenue position.
Looking for some new customers to be announced and good update on the status of PFS business.
RRM
November 2nd Conference Call and Amgens accelerated investment means big things coming !! $12+ imo.
Nice move today, $UNIS, will it continue?
I got out UNIS at 3.30 > It was a nice trade for many of us. IFAN has been the gangbuster play today. Up 180%.
UNIS was the best Nasdaq or for that matter any big board play I had for awhile today. Easy $$$. Congrats all. I had such a busy day everywhere but all solid green!
* * $UNIS Video Chart 10-24-16 * *
Link to Video - click here to watch the technical chart video
Saw that looks like the news today leaked late last week but $5+ not out of the question for sure especially with this type of float!
Huge, huge restructuring news today > Plus super low floater. Shorts are scared silly of low float momo movers.
Should close above $5.00+ today. + multi-day runner.
Read all the news out this morning. HUge upside catalysts!
Maybe only crazy one shorting/put $3.40? Anyone else?
UNIS > up 79% @ 3.14 super low float: news: Unilife Announces Filing of 2016 10-K
1 hour 37 minutes ago - DJNF
- Company Now Current with SEC Filings
YORK, Pa., Oct. 24, 2016 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) today announced that it has filed its Annual Report on Form 10-K for fiscal year 2016. In addition, the Company filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016 along with (i) an amendment to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2015; (ii) an amendment to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015; and (iii) an amendment to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2015.
The Company also announced the completion of the internal investigation, the accelerated purchase by Amgen, Inc. of $10 million of a senior secured convertible note, and provided an update on the restructuring of its business to prioritize key wearable injector customer programs.
The Company will hold an investor conference call on Wednesday, November 2, 2016 at 4:30 p.m. ET.
Investigation Complete
Unilife has completed its investigation into violations of the Company's policies and procedures and possible violations of law and regulation by the Company's former Chief Executive Officer, Alan Shortall, whose employment with the Company ceased on March 11, 2016, and its former Chairman, Jim Bosnjak, who resigned from the Company's Board of Directors on August 24, 2015.
The Company previously announced on July 28, 2016 that the investigation was substantially complete and summarized the results in its Current Report on Form 8-K filed with Securities and Exchange Commission on such date, including that the investigation had not identified any material financial loss to the Company. The investigation is now complete and has not identified any additional financial loss other than was already identified in the July 28, 2016 Form 8-K referenced above. Additional information regarding the findings of this investigation is available in the Company's Annual Report on Form 10-K filed today.
The Company today filed its Annual Report on Form 10-K for fiscal year 2016 and its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016, the filings of which had been delayed as a result of the investigation. In addition, the Company today filed amendments to the Company's Quarterly Reports on Form 10-Q for the fiscal quarters ended September 30, 2015 and December 31, 2015 and an amendment to the Company's Annual Report on Form 10-K for fiscal year 2015 to correct immaterial errors in the previously reported financial statements and to disclose certain material weaknesses in the Company's internal control over financial reporting and disclosure controls and procedures.
Wearable Injector Program
Unilife continues to focus on its targeted growth strategy of prioritizing active wearable injector programs with key pharmaceutical customers including Amgen, Sanofi, and MedImmune, the global biologics research and
I hold the thought the new hand held Auto Injectors were developed for AbbVie. The RD continues which might be driven from user input.
If not this week I believe that next week some sort of communication will be released to the marked.
First quarter is over so here is a humble thought they wrote off everything in 2016 and 2017 will be a new beginning for the company. JMHO
Yeah here is hoping for some positive
News.
Looks like new products are still being developed by Co. New hand held Auto Injector.
The big unknown was how the disposition of PFS business was handled. Sale/License/Royalty stream.
Hiring still going on. Unknown when they will release the financials. Need to remove this cloud.
Looking for Ryan to set the stage and update investors on his transformation efforts.
RRM
Recent report positives!! Deferred revenue up to 52 million.
RD. Still at 43m.
Machinery expense up 7m
Could PFS patents be sold? Sanofi...
Biodel issues to resolved soon.
Agreed. However delay, could extend out to Nov. Looks like they might resolve the BIODEL dispute soon.
Looking forward to the annual on the ASX tomorrow!
RRM
Looking forward to it
Looks like mid Sept before we get update on future of company!
It appears all the structural changes are in place.
New leadership team.
investigation complete.
RSU for employee incentives complete.
Focus on wearables.
Looking for Ryan and Ian to set the direction, with "integrity and clarity."
Cost structure has been greatly reduced.
Need update on programs, production, supply contracts, new customers and the status on the syringe business.
Update on AbbVie and Flextronics, patents and Imperium.
Nasdaq compliance plan submitted.
Need earnings call. ( will 3rd and 4th quarter calls be combined?)
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1466
|
Created
|
08/20/09
|
Type
|
Free
|
Moderators |
NEW - Annual General Meeting Presentation 2013
Unilife Medical Solutions (NASDAQ: UNIS) is an emerging medical device manufacturer with business segments that include pre-filled syringes for pharmaceutical companies to deliver injectable medications, sharps safety devices for healthcare facilities, and contract manufacturing of medical devices.
More than two billion prefilled syringes are currently used each year on a global basis and pharmaceutical companies are making the switch to products such as Unilife's safety syringe which are compliant with needle-stick prevention laws (e.g. Federal Needlestick Prevention Act, 2000).
Key differentiating features of Unilife's fully-integrated (within the barrel of the syringe) safety syringes include the following:
1.) a passive needle retraction system that is activated inside the body
2.) healthcare providers / shot administrators control the speed of needle retraction
3.) auto-disabling prevents re-use or tampering with used syringes.
The market opportunity for prefilled syringes includes 50 drugs (primary anti-coagulant / hematology medications, vaccines, and other biological agents) that are delivered by injection, including an estimated 3 billion prefilled syringes in use by 2012.
Unilife has a distinct advantage with a disruptive technology since there are currently no prefilled syringes to deliver medications with fully-integrated safety features so pharmaceutical companies must add these features - which adds to production / shipping costs and increases the overall packaging size by up to 60%, resulting in both waste disposal and marketing issues.
**********
*According to Markets and Markets, a full service market research company
**********
As an emerging global leader in innovative safety medical devices, Unilife welcomes enquiries from shareholders and analysts. If you are interested in Unilife investment opportunities, have questions or require more information, please contact the appropriate party below:
Shareholder / Analyst Enquiries United States:
Shareholder / Analyst Enquiries Australia: Jeff Carter (Ph: + 61 2 8346 6500)
RECENT CONFERENCE TRANSCRIPTS
Piper Jaffray 25th Annual Healthcare Conference - 12/4/13
Financial Summary - 2013
Key Ratios
"Designed by leading U.S. pharmaceutical architects, our modern $40MM global headquarters and production facility is situated on a 35 acre site in York, PA and sets a new standard for high-quality product manufacturing.
The 165,000 square-foot facility is as an integrated center for product innovation and commercial manufacturing, bringing together under one roof a seamless array of advanced operational capabilities, concentrated industry expertise and efficient quality assurance systems."
Australian Stock Price Chart (1/6th of US price)
Seeking Alpha BioMedReports.com
________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________________________________________________________________________________________
PRESENTATION (February 2010)
Please note..
SPAM messages & OFF TOPIC will be deleted.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |